Make 2nds Count

Rule Changes

Campaigning for wider Enhertu access after NICE approval

The National Institute for Health and Care Excellence published final guidance on October 7, confirming that about 1,000 people a year in England can get Enhertu for HER2-low advanced breast cancer. The decision ended a 26-month dispute over price, after the UK raised what it will pay per quality-adjusted life year from £30,000 to £35,000.

Updated Oct 24